297 related articles for article (PubMed ID: 8822928)
41. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
42. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.
Mosnier LO; Elisen MG; Bouma BN; Meijers JC
Thromb Haemost; 2001 Oct; 86(4):1057-64. PubMed ID: 11686324
[TBL] [Abstract][Full Text] [Related]
43. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
44. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN; Marx PF; Mosnier LO; Meijers JC
Thromb Res; 2001 Mar; 101(5):329-54. PubMed ID: 11297751
[TBL] [Abstract][Full Text] [Related]
45. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
Bajzar L
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2511-8. PubMed ID: 11116046
[TBL] [Abstract][Full Text] [Related]
46. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Jan; 85(1):5-11. PubMed ID: 11204587
[TBL] [Abstract][Full Text] [Related]
47. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
[TBL] [Abstract][Full Text] [Related]
48. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.
Bouma BN; Mosnier LO; Meijers JC; Griffin JH
Thromb Haemost; 1999 Dec; 82(6):1703-8. PubMed ID: 10613658
[TBL] [Abstract][Full Text] [Related]
49. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
50. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.
Foley JH; Nesheim ME
J Thromb Haemost; 2009 Mar; 7(3):453-9. PubMed ID: 19087221
[TBL] [Abstract][Full Text] [Related]
51. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation.
Bajzar L; Nesheim M
J Biol Chem; 1993 Apr; 268(12):8608-16. PubMed ID: 8473306
[TBL] [Abstract][Full Text] [Related]
52. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
[TBL] [Abstract][Full Text] [Related]
53. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
54. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
55. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
56. Thrombin-activatable fibrinolysis inhibitor.
Marx PF
Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
[TBL] [Abstract][Full Text] [Related]
57. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.
Mishra N; Vercauteren E; Develter J; Bammens R; Declerck PJ; Gils A
Thromb Haemost; 2011 Jul; 106(1):90-101. PubMed ID: 21544309
[TBL] [Abstract][Full Text] [Related]
58. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
59. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
